相关实验视频

Updated: Jun 4, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

马斯塔西马布:第一次批准

Yvette N Lamb¹

¹Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

|December 23, 2024

概括

针对血友病A和B的新型抗体治疗药物马斯塔西马布 (Marstacimab) 获得了美国和欧盟的监管批准. 这标志着血友病患者常规预防的重大进展.

科学领域:

血液学血液学血液学
药理学药理学是指药理学的学科.
免疫学免疫学免疫学

背景情况:

血友病A和B是遗传性出血障碍. 血友病A和B是遗传性出血障碍.
目前的治疗方法涉及因子替代疗法,这可能是繁的.
开发新的预防性治疗方法至关重要.

研究的目的:

总结一下marstacimab. 的发展里程碑.
为了突出其对血友病治疗的监管批准.

主要方法:

马斯塔西马布是一种人类单克隆免疫球蛋白G1抗体.
它针对组织因子通路抑制剂 (TFPI).
通过皮下注射进行.

主要成果:

马斯塔西马布于2024年10月11日获得美国FDA批准.
欧盟批准于2024年11月18日授予.
在没有抑制剂的血友病A和B患者的例行预防中获得批准.

结论:

马斯塔西马布代表了一个重要的治疗进步.
它为血友病患者提供了一个新的预防方案.
监管部门的批准为更广泛的患者接入铺平了道路.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...